How to Reconstitute BPC-157: Dosing Math (mg, mL, IU, Units)

What Is BPC-157 and Why Does Reconstitution Math Matter?

BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid peptide derived from a protective gastric protein sequence first isolated in human gastric juice. It is supplied as a lyophilized (freeze-dried) powder because the peptide degrades rapidly in aqueous solution at room temperature. Before any injection can occur, the powder must be dissolved in a sterile diluent, and then the resulting concentration must be converted into a volume the syringe can measure accurately.

Getting this math wrong has real consequences. Draw 10 times too much and you deliver 2,500 mcg instead of 250 mcg. Draw too little and you under-dose below the threshold used in preclinical tissue-repair studies. No FDA-approved product monograph exists for BPC-157 in humans, so the practitioner or patient must perform this arithmetic from first principles every time.

Why BPC-157 Is Not Measured in IU

Insulin, hCG, and some other biologics are measured in International Units (IU) because IU is a bioactivity standard defined by the WHO. BPC-157 has no WHO IU standard. The "units" you see on an insulin syringe are just volume markings calibrated to U-100 insulin (1 unit on the syringe = 0.01 mL). When peptide users say "10 units on an insulin syringe," they mean 0.10 mL. The peptide dose itself is expressed in micrograms (mcg) or milligrams (mg).

Regulatory Context

BPC-157 is not approved by the FDA for any human indication [1]. The FDA's 2023 guidance on bulk drug substances listed BPC-157 among compounds under evaluation for compounding eligibility, and its status has remained investigational [2]. All human use is therefore off-label or research-context, and reconstitution must follow USP <797> sterile compounding standards when performed by a pharmacy [3].

Supplies You Need Before You Start

Gathering everything before opening the vial prevents mid-procedure contamination. A single lapse in sterile technique can introduce gram-negative bacteria into the solution, and injecting contaminated peptide causes localized abscesses or systemic infection.

The Essential List

• BPC-157 lyophilized vial (commonly 5 mg)
• Bacteriostatic water for injection (BWFI), 0.9% benzyl alcohol as preservative, USP grade
• Two 23 to 25 gauge needles, 1 inch (one for drawing, one for injecting the diluent into the vial)
• One 1 mL or 3 mL Luer-lock syringe for reconstitution
• 100-unit insulin syringes (0.5 mL or 1 mL barrel) for dosing
• 70% isopropyl alcohol swabs
• Sharps container

Why Bacteriostatic Water, Not Sterile Water

Bacteriostatic water contains 0.9% benzyl alcohol, which inhibits microbial growth and extends the usable life of the reconstituted solution to approximately 28 days when refrigerated [4]. Sterile water for injection contains no preservative. A vial reconstituted with sterile water should be used within 24 hours or discarded, which is impractical for a 5 mg vial across a multi-week protocol. The United States Pharmacopeia (USP) permits benzyl alcohol as a preservative at concentrations up to 2% in multi-dose injectable preparations [3].

Do not use normal saline (0.9% NaCl) as your sole diluent. Saline lacks the antimicrobial preservative, and chloride ions may affect peptide solubility in some sequences, although direct BPC-157 stability data in saline versus BWFI remain limited in the published literature.

Step-by-Step Reconstitution Technique

Step 1: Disinfect All Rubber Stoppers

Wipe the rubber stoppers of both the BPC-157 vial and the BWFI vial with separate 70% isopropyl alcohol swabs. Allow 30 seconds of contact time before the alcohol evaporates fully. This is the minimum contact time recommended for skin antisepsis in the CDC guidelines on injection safety [5].

Step 2: Draw the Bacteriostatic Water

Attach a fresh 23-gauge needle to your 3 mL syringe. Draw 2 mL of BWFI. If your vial contains only 2 mg of BPC-157 and you prefer a different concentration, adjust accordingly using the formula in the next section. For the standard 5 mg vial, 2 mL is the recommended starting volume.

Step 3: Inject BWFI into the Peptide Vial

Insert the needle through the rubber stopper at a slight angle to avoid direct jet-stream disruption of the powder cake. Inject the BWFI slowly down the side of the glass vial wall. This prevents foaming and peptide denaturation from shear stress. Peptide denaturation caused by vigorous mixing has been documented in protein pharmaceutical literature as a source of aggregation and reduced bioavailability [6].

Step 4: Dissolve Gently, Never Vortex

Gently roll the vial between your palms for 30 to 60 seconds. Do not shake. Do not vortex. The solution should become clear and colorless. A faint yellowish tint can be normal depending on the manufacturer; cloudiness or visible particulates indicate contamination or degradation and the vial should be discarded.

Step 5: Label the Vial

Write the date of reconstitution, the concentration (2,500 mcg/mL), and your initials on the vial label. Store at 2 to 8 °C (standard refrigerator). Do not freeze the reconstituted solution.

The Core Dosing Math: mg, mcg, mL, and Syringe Units

This is the section most practitioners and patients get wrong. Work through each conversion in sequence.

Converting mg to mcg

1 mg = 1,000 mcg.

A 5 mg vial contains 5,000 mcg of BPC-157.

Calculating Concentration After Reconstitution

The formula is straightforward:

Concentration (mcg/mL) = Total peptide (mcg) / Volume of diluent added (mL)

For a 5 mg vial with 2 mL BWFI:

5,000 mcg / 2 mL = 2,500 mcg/mL

If you add 1 mL instead, concentration doubles to 5,000 mcg/mL, making each 0.1 mL draw equal to 500 mcg. That is a legitimate choice if your target dose is 500 mcg and you want to minimize injection volume. The table below shows common reconstitution scenarios.

| Vial size | BWFI added | Concentration | Volume for 250 mcg | Insulin syringe units | |-----------|------------|---------------|--------------------|-----------------------| | 5 mg | 1 mL | 5,000 mcg/mL | 0.05 mL | 5 units | | 5 mg | 2 mL | 2,500 mcg/mL | 0.10 mL | 10 units | | 5 mg | 5 mL | 1,000 mcg/mL | 0.25 mL | 25 units | | 2 mg | 1 mL | 2,000 mcg/mL | 0.125 mL | 12.5 units | | 2 mg | 2 mL | 1,000 mcg/mL | 0.25 mL | 25 units |

Converting mL to Insulin Syringe Units

A U-100 insulin syringe has 100 units marked across 1 mL. Each unit equals 0.01 mL. Therefore:

Units to draw = Dose (mL) × 100

For 0.10 mL: 0.10 × 100 = 10 units.

For 0.25 mL: 0.25 × 100 = 25 units.

This relationship holds for any U-100 insulin syringe, regardless of barrel size (0.3 mL, 0.5 mL, or 1 mL barrels all use the same unit scale).

Worked Example: 500 mcg Dose from a 5 mg / 2 mL Vial

1. Concentration = 5,000 mcg / 2 mL = 2,500 mcg/mL
2. Volume needed = 500 mcg / 2,500 mcg/mL = 0.20 mL
3. Insulin syringe units = 0.20 × 100 = 20 units

Draw to the "20" line on a U-100 syringe. Simple.

What Dose Range Appears in the Research Literature?

BPC-157 has no approved human dosing protocol, but preclinical and early translational research provides a frame of reference. Because no Phase III human RCTs exist, all human dose extrapolations are derived from animal studies scaled by body surface area or weight.

Animal Study Doses and Common Human Extrapolations

Preclinical rodent studies have used doses ranging from 10 mcg/kg to 10 mg/kg depending on the outcome studied [7]. A 70 kg adult scaled from a 10 mcg/kg rodent dose (using a simple weight-based conversion, not body-surface-area correction) yields approximately 700 mcg per day. Most practitioner-reported protocols in the peer-reviewed peptide and sports medicine literature cluster between 200 mcg and 500 mcg per injection, given once or twice daily, for 4 to 12 weeks [8].

A 2018 review of BPC-157 gastroprotective and systemic effects by Sikiric et al., published in Current Pharmaceutical Design, documented consistent efficacy in rodent models at 10 mcg/kg administered intraperitoneally, with effects on nitric oxide pathways, growth hormone receptor expression, and tendon fibroblast proliferation [7].

Route Matters for Dose Selection

Subcutaneous and intramuscular bioavailability for peptides differ from oral or intraperitoneal routes used in animal research. Subcutaneous peptide absorption is generally slower and the peak plasma concentration lower than IV, though the area-under-the-curve may be comparable for short peptides below 2,000 daltons. BPC-157 has a molecular weight of approximately 1,419 daltons, placing it in a range where SC absorption is expected to be reasonable, though direct human pharmacokinetic data remain unpublished as of this writing.

Injection Technique: SC vs. IM

Subcutaneous Injection

SC injection deposits the peptide into the fatty tissue layer just beneath the skin. Common sites include the abdomen (at least 2 inches from the navel), the lateral thigh, and the back of the upper arm. Pinch a fold of skin, insert the needle at a 45-degree angle (or 90 degrees if the fold is thick), inject slowly, and withdraw. Rotate sites with every injection to prevent lipohypertrophy, a complication well-documented with repeated SC insulin injections in the same location [9].

Intramuscular Injection

IM injection targets the deltoid, vastus lateralis, or ventrogluteal muscle. Use a 25-gauge, 1-inch needle for most adults. Insert at 90 degrees. Aspirating before injection is no longer universally recommended by the CDC for most IM sites but remains standard for ventrogluteal sites when the injector is less experienced [5]. IM absorption is generally faster than SC for most peptides.

Storage and Stability After Reconstitution

Lyophilized BPC-157 is stable at room temperature for months when kept dry and away from UV light, though long-term accelerated stability data specific to BPC-157 are sparse in the peer-reviewed literature. Once reconstituted with BWFI, the solution should be:

• Stored at 2 to 8 °C (do not freeze)
• Used within 28 days
• Protected from light (aluminum foil or amber vial preferred)
• Discarded if any particulates appear, color changes occur, or the vial was left unrefrigerated for more than 4 hours

Benzyl alcohol, the preservative in BWFI, is effective against most common bacterial contaminants but does not sterilize an already-contaminated solution. The 28-day limit is a USP <797> convention for multi-dose vials with preservative, not a peptide-specific stability endpoint [3].

Peptide oxidation is the primary chemical degradation pathway in aqueous solution. Methionine-containing peptides are especially susceptible. BPC-157 does not contain methionine in its sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val), which may confer relatively better oxidative stability compared to methionine-rich sequences, though this has not been confirmed by independent published stability testing.

Safety, Contamination Risks, and Red Flags

Source Quality and Purity

BPC-157 sold for "research purposes" in the United States operates outside FDA manufacturing oversight. A 2020 analysis of research-chemical peptide samples found that a meaningful proportion of tested vials contained incorrect peptide concentrations, wrong sequences, or detectable bacterial endotoxins [10]. The FDA has issued multiple warning letters to online peptide suppliers [2].

If a vial is sourced outside a licensed compounding pharmacy operating under USP <797> standards, there is no third-party verification of peptide identity, concentration, or sterility. The American Society of Health-System Pharmacists (ASHP) states that sterile compounding outside USP <797> guidelines poses direct patient harm risk [11].

Signs of a Contaminated or Degraded Vial

• Cloudy or particulate solution after full dissolution
• Unusual color (deep yellow, brown, or pink)
• Visible flakes or film on the glass
• Pain, redness, or warmth at the injection site beyond 48 hours (suggests localized infection)
• Fever within 12 hours of injection (suggests systemic contamination)

Any of these findings should prompt immediate cessation of use and medical evaluation.

Benzyl Alcohol Warning in Neonates

BWFI contains benzyl alcohol. The FDA has issued a specific safety communication warning against using benzyl alcohol-preserved products in neonates and low-birth-weight infants due to "gasping syndrome," a potentially fatal toxicity [4]. BPC-157 is not indicated in any pediatric population, but this warning is noted here for completeness.

Practical Checklist Before Your First Injection

1. Confirm vial label: peptide name, lot number, and mg quantity.
2. Confirm BWFI label: USP grade, benzyl alcohol 0.9%, and expiration date.
3. Calculate your target concentration using the formula above and write it on the vial.
4. Confirm the syringe markings: U-100 scale with 0.01 mL per unit.
5. Disinfect stoppers with 70% isopropyl alcohol, wait 30 seconds.
6. Inject BWFI gently down the vial wall. Roll, do not shake.
7. Draw your calculated volume. Confirm the unit marking matches your math before injecting.
8. Inject SC or IM per your protocol. Dispose of needle immediately in a sharps container.
9. Record date, dose in mcg, volume in mL, and injection site in a log.

Step 9 is not optional. If a vial turns out to be under- or over-potent, a detailed injection log allows you to reconstruct the exposure and adjust future doses accurately.